How important is to eradicate minimal residual disease in indolent non-Hodgkin’s lymphoma?

Published: June 8, 2009
Abstract Views: 172
PDF: 354
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

In Follicular non Hodgkin’s Lymphoma (FL-NHL) the molecular diagnosis and monitoring of the chimeric BCL2/IgH gene generated by the t(14;18)is an important tool in the diagnostic work-up at diagnosis and during the clinical follow-up. Although the clinical significance of circulating BCL2/IgH+ cells is still controversial, the persistence of these cells after conventional or high dose chemotherapy programs correlates with a shorter clinical remission.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Supporting Agencies

How to Cite

Rambaldi, A. (2009). How important is to eradicate minimal residual disease in indolent non-Hodgkin’s lymphoma?. Hematology Meeting Reports (formerly Haematologica Reports), 2(7). https://doi.org/10.4081/hmr.v2i7.424